Valeant ($VRX), which is trying to overcome resistance from the management of Allergan ($AGN) for its $53 billion buyout offer, has filed a new presentation with the SEC in preparation for an investor meeting. Refuting Allergan's contention that its growth has been mostly tied to its nonstop M&A action, Valeant says the data shows 12% organic growth at Bausch & Lomb since it bought it out last year and takes credit for 90% of that improvement. The announcement does not mention the thousands of employees who got the boot as a result of the merger. Release | More